Definitive Healthcare (NASDAQ:DH) Cut to "Neutral" at BTIG Research

BTIG Research cut shares of Definitive Healthcare (NASDAQ:DH - Free Report) from a buy rating to a neutral rating in a research report sent to investors on Friday morning, Marketbeat reports.

DH has been the subject of several other research reports. The Goldman Sachs Group reduced their target price on shares of Definitive Healthcare from $4.50 to $3.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Barclays cut their target price on shares of Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating for the company in a research note on Monday, March 3rd. Finally, Needham & Company LLC restated a "hold" rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $5.10.

Definitive Healthcare Stock Down 3.0%

DH stock traded down $0.11 during trading on Friday, hitting $3.58. 812,734 shares of the company's stock traded hands, compared to its average volume of 831,821. The firm has a market capitalization of $386.51 million, a P/E ratio of -1.15, a PEG ratio of 4.06 and a beta of 1.48. Definitive Healthcare has a 1 year low of $2.15 and a 1 year high of $6.27. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.33. The business has a fifty day simple moving average of $2.71 and a two-hundred day simple moving average of $3.87.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. The company had revenue of $59.19 million during the quarter, compared to the consensus estimate of $56.20 million. During the same period last year, the firm earned $0.08 earnings per share. Definitive Healthcare's revenue was down 6.8% compared to the same quarter last year. Sell-side analysts anticipate that Definitive Healthcare will post 0.16 EPS for the current year.

Institutional Investors Weigh In On Definitive Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC grew its position in Definitive Healthcare by 318.8% during the 3rd quarter. Barclays PLC now owns 81,916 shares of the company's stock worth $366,000 after purchasing an additional 62,354 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Definitive Healthcare by 431.7% in the third quarter. JPMorgan Chase & Co. now owns 222,090 shares of the company's stock valued at $993,000 after purchasing an additional 180,323 shares during the period. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Definitive Healthcare by 34.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 50,886 shares of the company's stock valued at $209,000 after purchasing an additional 12,946 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Definitive Healthcare by 3,652.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,980 shares of the company's stock valued at $29,000 after purchasing an additional 6,794 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of Definitive Healthcare by 44.6% in the fourth quarter. SG Americas Securities LLC now owns 27,189 shares of the company's stock valued at $112,000 after purchasing an additional 8,387 shares in the last quarter. 98.67% of the stock is currently owned by institutional investors and hedge funds.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.